Miranda Lankas

Patients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.

Patients treated with darolutamide were less likely to develop disease metastasis or discontinue treatment 6-18 months after treatment initiation compared with enzalutamide or apalutamide.

The use of iberdomide alone or with anti-CD20 antibodies show efficacy in patients with relapsed or refractory lymphoma.

Pre- and postmenopausal patient with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, according to RxPONDER PRO substudy results presented during SABCS 2022.

An updated analysis of the KEYNOTE-365 study of pembrolizumab plus abiraterone showed that patients with chemotherapy-naive metastatic castration-resistant prostate cancer had prostate-specific antigen responses.